BR0210630A - Sistema fornecedor de liberação prolongada - Google Patents
Sistema fornecedor de liberação prolongadaInfo
- Publication number
- BR0210630A BR0210630A BR0210630-2A BR0210630A BR0210630A BR 0210630 A BR0210630 A BR 0210630A BR 0210630 A BR0210630 A BR 0210630A BR 0210630 A BR0210630 A BR 0210630A
- Authority
- BR
- Brazil
- Prior art keywords
- implant
- tablet
- extended release
- release
- mini
- Prior art date
Links
- 238000013265 extended release Methods 0.000 title abstract 4
- 239000007943 implant Substances 0.000 abstract 5
- 239000003826 tablet Substances 0.000 abstract 3
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 2
- 239000008185 minitablet Substances 0.000 abstract 2
- 230000036765 blood level Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Anesthesiology (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Reproductive Health (AREA)
Abstract
"SISTEMA FORNECEDOR DE LIBERAçãO PROLONGADA". Aparelho de liberação prolongada incluindo pelo menos um implante de minicomprimido de liberação prolongada, o ou cada implante de minicomprimido incluindo: uma composição farmaceuticamente ativa compreendendo pelo menos um componente farmaceuticamente ativo, e um veículo para este e o ou cada implante de comprimido sendo do tipo comprimido revestido ou bastonete coberto, cada implante de minicomprimido sendo aproximadamente 0,1 a 0,5 vezes o comprimento e/ou diâmetro de um único comprimido de liberação imediata capaz de providenciar o desejado nível sang³íneo limite, dependendo do ativo farmacêutico desejado, e tendo uma carga comercial de aproximadamente 30% a 70% em peso da carga útil total de um tratamento para liberação imediata equivalente durante um período equivalente realizado durante um período equivalente, o aparelho de liberação prolongada providenciando, em uso liberação de ordem zero do ativo farmacêutico.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPR6024A AUPR602401A0 (en) | 2001-06-29 | 2001-06-29 | Sustained release delivery system |
PCT/AU2002/000866 WO2003009833A1 (en) | 2001-06-29 | 2002-07-01 | Sustained release delivery system |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0210630A true BR0210630A (pt) | 2004-07-27 |
Family
ID=3829990
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0210630-2A BR0210630A (pt) | 2001-06-29 | 2002-07-01 | Sistema fornecedor de liberação prolongada |
Country Status (9)
Country | Link |
---|---|
US (1) | US8197839B2 (pt) |
EP (1) | EP1411905A4 (pt) |
JP (1) | JP4913321B2 (pt) |
CN (1) | CN1536988A (pt) |
AU (2) | AUPR602401A0 (pt) |
BR (1) | BR0210630A (pt) |
CA (1) | CA2452075C (pt) |
NZ (1) | NZ529858A (pt) |
WO (1) | WO2003009833A1 (pt) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6375972B1 (en) | 2000-04-26 | 2002-04-23 | Control Delivery Systems, Inc. | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
WO2003022242A1 (en) * | 2001-09-11 | 2003-03-20 | Smart Drug Systems Inc | Preparation of sustained release pharmaceutical composition |
EP1696822B1 (en) * | 2003-11-13 | 2010-03-17 | PSivida US Inc. | Injectable sustained release implant having a bioerodible matrix core and a bioerodible skin |
CN101001640A (zh) * | 2004-05-31 | 2007-07-18 | 斯玛特药物***公司 | 缓释组合物 |
CA2575988C (en) | 2004-08-04 | 2014-02-18 | Brookwood Pharmaceuticals, Inc. | Methods for manufacturing delivery devices and devices thereof |
US20110034498A1 (en) * | 2006-03-24 | 2011-02-10 | Mcgovern Karen J | Dosing regimens for the treatment of cancer |
US20090005869A1 (en) * | 2006-12-15 | 2009-01-01 | University Of Virginia Patent Foundation | Device which Attaches into a Joint and Carries a Payload of Controlled Release Drugs and Related Method thereof |
NZ552290A (en) * | 2006-12-21 | 2009-05-31 | Bomac Research Ltd | Tablet fomulation |
TWI433674B (zh) | 2006-12-28 | 2014-04-11 | Infinity Discovery Inc | 環杷明(cyclopamine)類似物類 |
EP2222281B1 (en) | 2007-12-20 | 2018-12-05 | Evonik Corporation | Process for preparing microparticles having a low residual solvent volume |
US20090181997A1 (en) * | 2007-12-27 | 2009-07-16 | Grayzel David | Therapeutic cancer treatments |
CN104059124A (zh) | 2007-12-27 | 2014-09-24 | 无限药品股份有限公司 | 立体选择性还原的方法 |
US20100297118A1 (en) * | 2007-12-27 | 2010-11-25 | Macdougall John | Therapeutic Cancer Treatments |
US9005649B2 (en) | 2009-07-14 | 2015-04-14 | Board Of Regents, The University Of Texas System | Methods for making controlled delivery devices having zero order kinetics |
WO2011017551A1 (en) | 2009-08-05 | 2011-02-10 | Infinity Pharmaceuticals, Inc. | Enzymatic transamination of cyclopamine analogs |
WO2011088404A1 (en) * | 2010-01-15 | 2011-07-21 | Infinity Pharmaceuticals , Inc | Treatment of fibrotic conditions using hedgehog inhibitors |
WO2012037217A1 (en) | 2010-09-14 | 2012-03-22 | Infinity Pharmaceuticals, Inc. | Transfer hydrogenation of cyclopamine analogs |
ITTO20111188A1 (it) | 2011-12-22 | 2013-06-23 | Vhit Spa | Pompa a cilindrata variabile e metodo di regolazione della sua cilindrata |
TW201618783A (zh) | 2014-08-07 | 2016-06-01 | 艾森塔製藥公司 | 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法 |
EP3302428A1 (en) | 2015-06-04 | 2018-04-11 | Pellepharm Inc. | Topical formulations for delivery of hedgehog inhibitor compounds and use thereof |
FI20155779A (fi) * | 2015-10-30 | 2017-05-01 | Solani Therapeutics Ltd | Ei-steroidaalisen anti-inflammatorisen lääkkeen hidastetusti vapautuva annostelu |
CN111989068A (zh) | 2018-05-24 | 2020-11-24 | 塞拉尼斯伊娃高性能聚合物公司 | 用于持续释放大分子药物化合物的可植入器件 |
MX2020012458A (es) | 2018-05-24 | 2021-04-28 | Celanese Eva Performance Polymers Llc | Dispositivo implantable para liberacion sostenida de un compuesto de farmaco macromolecular. |
CN110559431B (zh) * | 2019-10-11 | 2023-02-28 | 南京农业大学 | 一种巨型艾美耳球虫纳米亚单位疫苗及其制备方法和应用 |
CN116687882A (zh) * | 2023-07-06 | 2023-09-05 | 杭州高成生物营养技术有限公司 | 一种布洛芬缓释小丸及其制备方法 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3279996A (en) * | 1962-08-28 | 1966-10-18 | Jr David M Long | Polysiloxane carrier for controlled release of drugs and other agents |
US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4013785A (en) * | 1975-03-21 | 1977-03-22 | Bristol-Myers Company | Apap tablet containing fumed silica and process for manufacturing same |
US4111202A (en) * | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system for the controlled and delivery of agent over time |
US4331652A (en) * | 1979-09-12 | 1982-05-25 | Eli Lilly And Company | Controlled release parasitic formulations and method |
US4578075A (en) * | 1982-12-20 | 1986-03-25 | Alza Corporation | Delivery system housing a plurality of delivery devices |
US4681583A (en) * | 1982-12-20 | 1987-07-21 | Alza Corporation | System for dispersing drug in biological environment |
DE3681348D1 (de) | 1985-06-11 | 1991-10-17 | Teijin Ltd | Oral-arzneizubereitung mit retardwirkung. |
SE444801B (sv) | 1985-06-28 | 1986-05-12 | Johan Magnus Ullman | Fender |
US4786501A (en) | 1985-07-15 | 1988-11-22 | International Minerals & Chemical Corp. | Cylindrical implants for the controlled release of growth hormones |
US5342622A (en) | 1986-05-16 | 1994-08-30 | The State Of Victoria | Subdermal biocompatible implants |
JPH01500899A (ja) * | 1986-05-16 | 1989-03-30 | ザ・ステイト・オブ・ビクトリア | 生物適合性インプラント |
US5028430A (en) * | 1987-05-08 | 1991-07-02 | Syntex (U.S.A.) Inc. | Delivery systems for the controlled administration of LHRH analogs |
US5035891A (en) * | 1987-10-05 | 1991-07-30 | Syntex (U.S.A.) Inc. | Controlled release subcutaneous implant |
US5034229A (en) * | 1988-12-13 | 1991-07-23 | Alza Corporation | Dispenser for increasing feed conversion of hog |
JPH0618958B2 (ja) * | 1989-03-08 | 1994-03-16 | 株式会社クラレ | 多層容器および包装体 |
ES2042292T3 (es) | 1989-03-17 | 1993-12-01 | Pitman-Moore, Inc. | Dispositivo de administracion de proteinas macromoleculares por liberacion controlada. |
JP2738881B2 (ja) * | 1989-06-21 | 1998-04-08 | ブラウン ユニバーシティ リサーチ ファウンデイション | 神経治療システム |
US5091185A (en) | 1990-06-20 | 1992-02-25 | Monsanto Company | Coated veterinary implants |
AU660290B2 (en) | 1990-08-09 | 1995-06-22 | Endocon, Inc. | Multiple drug delivery system |
NZ239370A (en) * | 1990-08-22 | 1994-04-27 | Merck & Co Inc | Bioerodible implantable controlled release dosage form comprising a poly(ortho ester) or a polyacetal with an active agent incorporated into the chain backbone |
IS3778A7 (is) * | 1990-10-31 | 1992-05-02 | Amgen Inc. | Aðferð til að gefa dýrum vaxtarhormón, þar sem gefnu magni er stýrt |
US5211951A (en) * | 1991-07-24 | 1993-05-18 | Merck & Co., Inc. | Process for the manufacture of bioerodible poly (orthoester)s and polyacetals |
JPH06321803A (ja) * | 1993-05-17 | 1994-11-22 | Kirin Brewery Co Ltd | 水溶性ペプチドホルモンの徐放性製剤 |
JP3720386B2 (ja) * | 1993-12-27 | 2005-11-24 | 住友製薬株式会社 | 薬物放出制御製剤 |
KR100210509B1 (ko) * | 1996-01-10 | 1999-07-15 | 성재갑 | 지속성 동물 성장 호르몬 제형 및 이의 제조 방법 |
FR2745180B1 (fr) | 1996-02-23 | 1998-05-07 | Dow Corning Sa | Procede de fabrication de dispositifs a liberation controlee |
EP1014970A1 (en) * | 1997-09-23 | 2000-07-05 | Pfizer Limited | Parasiticidal formulations |
AUPP279698A0 (en) * | 1998-04-03 | 1998-04-30 | Sunscape Developments Limited | Sustained release formulation |
EP1098610B1 (en) | 1998-07-17 | 2009-04-15 | Pacira Pharmaceuticals, Inc. | Biodegradable compositions for the controlled release of encapsulated substances |
WO2000013666A1 (en) * | 1998-09-05 | 2000-03-16 | Seung Jin Lee | Biodegradable particulate polymeric preparation and process for producing thereof |
US6756048B1 (en) * | 1998-09-10 | 2004-06-29 | Sumitomo Pharmaceuticals Company, Limited | Long time drug-sustained release preparation |
US6645192B2 (en) * | 1998-09-30 | 2003-11-11 | Ivy Animal Health, Inc. | Pellet implant system for immediate and delayed release of antiparasitic drug |
EP2266542A3 (en) | 1998-10-01 | 2013-07-31 | Elan Pharma International Limited | Controlled release nanoparticulate compositions |
US6596296B1 (en) | 1999-08-06 | 2003-07-22 | Board Of Regents, The University Of Texas System | Drug releasing biodegradable fiber implant |
JP4230621B2 (ja) | 1999-08-12 | 2009-02-25 | 住友ゴム工業株式会社 | 空気入りタイヤ |
TW524696B (en) * | 1999-11-10 | 2003-03-21 | Sumitomo Pharma | Sustained-release drug formulations |
JP4757995B2 (ja) * | 1999-11-10 | 2011-08-24 | 大日本住友製薬株式会社 | 薬物放出製剤 |
WO2001037811A1 (en) * | 1999-11-22 | 2001-05-31 | Akzo Nobel N.V. | Composition allowing predefined and controlled release of active ingredient, preparation thereof and use |
US6998137B2 (en) | 2000-04-07 | 2006-02-14 | Macromed, Inc. | Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix |
JP4504122B2 (ja) | 2004-07-02 | 2010-07-14 | 株式会社マキタ | 生垣バリカン |
-
2001
- 2001-06-29 AU AUPR6024A patent/AUPR602401A0/en not_active Abandoned
-
2002
- 2002-07-01 AU AU2002344686A patent/AU2002344686B2/en not_active Expired
- 2002-07-01 NZ NZ529858A patent/NZ529858A/en not_active IP Right Cessation
- 2002-07-01 EP EP02742516A patent/EP1411905A4/en not_active Withdrawn
- 2002-07-01 JP JP2003515226A patent/JP4913321B2/ja not_active Expired - Fee Related
- 2002-07-01 CN CNA028131185A patent/CN1536988A/zh active Pending
- 2002-07-01 CA CA2452075A patent/CA2452075C/en not_active Expired - Fee Related
- 2002-07-01 BR BR0210630-2A patent/BR0210630A/pt not_active IP Right Cessation
- 2002-07-01 US US10/482,335 patent/US8197839B2/en active Active
- 2002-07-01 WO PCT/AU2002/000866 patent/WO2003009833A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2003009833A1 (en) | 2003-02-06 |
CN1536988A (zh) | 2004-10-13 |
CA2452075C (en) | 2012-08-14 |
JP2004535473A (ja) | 2004-11-25 |
US20040247643A1 (en) | 2004-12-09 |
AU2002344686B2 (en) | 2008-07-31 |
NZ529858A (en) | 2006-02-24 |
CA2452075A1 (en) | 2003-02-06 |
EP1411905A1 (en) | 2004-04-28 |
AUPR602401A0 (en) | 2001-07-26 |
US8197839B2 (en) | 2012-06-12 |
EP1411905A4 (en) | 2008-01-23 |
JP4913321B2 (ja) | 2012-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0210630A (pt) | Sistema fornecedor de liberação prolongada | |
ES2155124T3 (es) | Composiciones farmaceuticas liquidas a base de hormonas tiroideas. | |
BRPI0412526A (pt) | composto, uso de um composto, composição farmacêutica, formulação em aerossol farmacêutica, e, método para o tratamento de um paciente humano ou animal com uma condição anti-inflamatória e/ou alérgica | |
SE9704186D0 (sv) | New composition of matter | |
ATE275393T1 (de) | Feste dispersionen mit nitrataktiven wirkstoffen | |
BRPI0611400A8 (pt) | Formulações contendo xiloglicano muco-adesivas úteis em dispositivos médicos e em formulações farmacêuticas | |
DE69906518D1 (de) | Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis | |
DE50211045D1 (de) | Medizinische aerosolformulierungen | |
BR0212434A (pt) | Dispositivos médicos contendo análogos de rapamicina | |
DE60220049D1 (de) | Pharmazeutische zusammensetzungen enthaltend eine feste dispersion eines im wasser schwerlöslichen arzneimittels und ein löslichkeitsteigerndes polymer | |
BR0215380A (pt) | Pó micronizado farmacêutico ou nutracêutico de liberação imediata e utilização do mesmo | |
EE05404B1 (et) | Kinuklidiini derivaat, selle saamine ja kasutamine ravimi valmistamiseks, mis on ette nhtud respiratoorsete, kuseelundite v?i mao-soolte haiguste ravimiseks, ning seda sisaldav ravimkompositsioon | |
HUP9903732A2 (hu) | cGMP-szintjét növelő szerek alkalmazása a jóindulatú prosztatatúltengés kezelésére szolgáló gyógyszerkészítmények előállítására | |
BR0210631A (pt) | Composição farmacêutica de liberação prolongada | |
DE69919179D1 (de) | Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen | |
BR0309115A (pt) | Composição farmacêutica em pó seco, método de tratamento ou profilaxia de distúrbios respiratórios, uso de uma composição farmacêutica em pó seco, dispositivo de inalação, embalagem de medicamento, e, uso de carboidratos derivados particulados em composição farmacêutica em pó seco | |
ID18079A (id) | Komposisi farmasi yang mengandung bahan pemercepat osteogenesis | |
BR0309057A (pt) | Formulações lìquidas com baixa dosagem em entecavir e uso | |
BR0015225A (pt) | Tratamento de enfisema utilizando antagonistas retinóides seletivos para rar | |
BR0211008A (pt) | Combinação de ingrediente ativo, uso de uma combinação de ingrediente ativo e método para a terapia farmacológia de uma substância que causa dependência ou que seja intoxicante | |
BRPI0414305A (pt) | sistema de liberação de drogas por via oral | |
BR0010983A (pt) | Preparações para a aplicação de agentes antiinflamatórios | |
BR0112839A (pt) | Composição de eletriptano em partìculas | |
BR0214159A (pt) | Sistema farmacêutico radiopaco de liberação prolongada | |
DE60320034D1 (de) | Behandlung von mastitis mit einer kombination aus prednisolon und cephalosporin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: VIRBAC CORPORATION (US) Free format text: TRANSFERIDO DE: SMART DRUG SYSTEMS INC. |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 13A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2313 DE 05-05-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
B15K | Others concerning applications: alteration of classification |
Ipc: A61K 9/00 (2006.01), A61K 9/20 (2006.01), A61K 9/2 |